These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21190190)

  • 21. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
    Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
    Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix.
    Ferreira Costa AP; Gonçalves AK; Machado PRL; Souza LBFC; Sarmento A; Cobucci RNO; Giraldo PC; Witkin SS
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2313-2317. PubMed ID: 30141308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
    Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
    Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
    Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
    Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of Immunoglobulin A/G Responses During 3 Doses of the Human Papillomavirus-16/18 ASO4-Adjuvanted Vaccine.
    Gonçalves AK; Giraldo PC; Farias KJ; Machado PR; Costa AP; de Souza LC; Crispim JC; Eleutério J; Witkin SS
    Sex Transm Dis; 2016 May; 43(5):335-9. PubMed ID: 27100772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.
    De Carvalho N; Teixeira J; Roteli-Martins CM; Naud P; De Borba P; Zahaf T; Sanchez N; Schuind A
    Vaccine; 2010 Aug; 28(38):6247-55. PubMed ID: 20643092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women.
    Sow PS; Watson-Jones D; Kiviat N; Changalucha J; Mbaye KD; Brown J; Bousso K; Kavishe B; Andreasen A; Toure M; Kapiga S; Mayaud P; Hayes R; Lebacq M; Herazeh M; Thomas F; Descamps D
    J Infect Dis; 2013 Jun; 207(11):1753-63. PubMed ID: 23242542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.
    Zhu F; Li J; Hu Y; Zhang X; Yang X; Zhao H; Wang J; Yang J; Xia G; Dai Q; Tang H; Suryakiran P; Datta SK; Descamps D; Bi D; Struyf F
    Hum Vaccin Immunother; 2014; 10(7):1795-806. PubMed ID: 25424785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.
    Schwarz TF; Spaczynski M; Schneider A; Wysocki J; Galaj A; Perona P; Poncelet S; Zahaf T; Hardt K; Descamps D; Dubin G;
    Vaccine; 2009 Jan; 27(4):581-7. PubMed ID: 19022320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
    Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
    J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.
    Petäjä T; Keränen H; Karppa T; Kawa A; Lantela S; Siitari-Mattila M; Levänen H; Tocklin T; Godeaux O; Lehtinen M; Dubin G
    J Adolesc Health; 2009 Jan; 44(1):33-40. PubMed ID: 19101456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.
    Garcia-Sicilia J; Schwarz TF; Carmona A; Peters K; Malkin JE; Tran PM; Behre U; Iturbe EB; Catteau G; Thomas F; Dobbelaere K; Descamps D; Dubin G;
    J Adolesc Health; 2010 Feb; 46(2):142-51. PubMed ID: 20113920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial.
    Lin L; Parra MM; Sierra VY; Cespedes AS; Granados MA; Luque A; Damaso S; Castrejon Alba MM; Romano-Mazzotti L; Struyf F
    Pediatr Infect Dis J; 2018 Apr; 37(4):e93-e102. PubMed ID: 29424799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.
    Leroux-Roels G; Haelterman E; Maes C; Levy J; De Boever F; Licini L; David MP; Dobbelaere K; Descamps D
    Clin Vaccine Immunol; 2011 Sep; 18(9):1510-8. PubMed ID: 21734063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term persistence of immune response to the AS04-adjuvanted HPV-16/18 vaccine in Chinese girls aged 9-17 years: Results from an 8-9-year follow-up phase III open-label study.
    Hu Y; Zhang X; He Y; Ma Z; Xie Y; Lu X; Xu Y; Zhang Y; Jiang Y; Xiao H; Struyf F; Folschweiller N; Jiang J; Poncelet S; Karkada N; Jastorff A; Borys D
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):392-399. PubMed ID: 32780946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.
    Dessy FJ; Giannini SL; Bougelet CA; Kemp TJ; David MP; Poncelet SM; Pinto LA; Wettendorff MA
    Hum Vaccin; 2008; 4(6):425-34. PubMed ID: 18948732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial.
    Konno R; Tamura S; Dobbelaere K; Yoshikawa H
    Int J Gynecol Cancer; 2010 Jul; 20(5):847-55. PubMed ID: 20606533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
    Szarewski A
    Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.